Respiratory Medicine
Volume 104, Issue 2 , Pages 188-196 , February 2010

Effect of omalizumab on peripheral blood eosinophilia in allergic asthma

  • M. Massanari

      Affiliations

    • Novartis Pharmaceuticals Corp., East Hanover, NJ 07936-1080, USA
    • Corresponding Author InformationCorresponding author. Tel.: +44 862 778 7843. Mobile: 973 896 2802.
    • ,
  • S.T. Holgate

      Affiliations

    • Southampton General Hospital, Southampton, UK
    • ,
  • W.W. Busse

      Affiliations

    • University of Wisconsin, USA
    • ,
  • P. Jimenez

      Affiliations

    • Novartis Pharmaceuticals Corp., East Hanover, NJ 07936-1080, USA
    • ,
  • F. Kianifard

      Affiliations

    • Novartis Pharmaceuticals Corp., East Hanover, NJ 07936-1080, USA
    • ,
  • R. Zeldin

      Affiliations

    • Novartis Pharmaceuticals Corp., East Hanover, NJ 07936-1080, USA

Received 23 December 2008 ,Accepted 17 September 2009.

References 

  1. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2007 (issued January 1995, revised 2002, 2006, 2007). Available from: http://www.ginasthma.org.
  2. Arbes SJ, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2007;120:1139–1145
  3. Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2003;111:S486–S494
  4. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459–465
  5. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med. 1989;320:271–277
  6. Adamko DJ, Odemuyiwa SO, Vethanayagam D, Moqbel R. The rise of the phoenix: the expanding role of the eosinophil in health and disease. Allergy. 2005;60:13–22
  7. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanović R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med. 2000;161:9–16
  8. Petsky HL, Kynaston JA, Turner C, Li AM, Cates CJ, Lasserson TJ, et al. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults (Review). Cochrane Database Syst Rev. 2007;(Issue 2):(CD005603)
  9. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360:1715–1721
  10. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–316
  11. Vignola AM, Humbert M, Bousquet J, Boulet L-P, Hedgecock S, Blogg M, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis (SOLAR). Allergy. 2004;59:709–717
  12. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Della Cioppa G, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184–190
  13. Solèr M, Matz J, Townley R, Buhl R, O'Brian J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254–261Erratum in: Eur Respir J 2001;18:739–40
  14. Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GA, Chung KF, et al. Efficacy and tolerability of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34:632–638
  15. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60:302–308
  16. Chipps B, Buhl R, Beeh K-M, Fox H, Thomas K, Reisner C. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin. 2006;22:2201–2208
  17. Djukanović R, Wilson SJ, Kraft M, Jarjour N, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170:583–593
  18. MacGlashan DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Down-regulation of FcɛRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438–1445
  19. Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, et al. Omalizumab rapidly decreases nasal allergic response and FɛRI on basophils. J Allergy Clin Immunol. 2004;113:297–302
  20. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell FcɛRI expression and function. J Allergy Clin Immunol. 2004;114:527–530
  21. Prussin C, Griffith DT, Boesel K, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcɛRI expression. J Allergy Clin Immunol. 2003;112:1147–1154
  22. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol. 2003;91:154–159
  23. Buhl R, Solèr M, Matz J, Townley R, O'Brien J, Noga O, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J. 2002;20:73–78
  24. Casale TB, Bernstein L, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol. 1997;100:110–121
  25. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system. 2nd ed.. Cary, North Carolina: SAS Institute, Inc.; 2000;
  26. Kianifard F, Gallo PP. Poisson regression analysis in clinical research. J Biopharm Stat. 1995;5:115–129
  27. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol. 2003;131:46–52
  28. Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006;117:1493–1499
  29. Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Ädelroth E, et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol. 2002;110:68–71
  30. Lee YC, Lee KH, Lee HB, Rhee YK. Serum levels of interleukins (IL)-4, IL-5, IL-13, and interferon-gamma in acute asthma. J Asthma. 2001;38:665–671
  31. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol. 1999;17:255–281
  32. Seminario MC, Saini SS, MacGlashan DW, Bochner BS. Intracellular expression and release of FcɛRI α by human eosinophils. J Immunol. 1999;162:6893–6900
  33. Kita H, Kaneko M, Bartemes KR, Weiler DA, Schimming AW, Reed CE, et al. Does IgE bind to and activate eosinophils from patients with allergy?. J Immunol. 1999;1(62):6901–6911
  34. Smith SJ, Ying S, Meng Q, Sullivan MH, Barkans J, Kon OM, et al. Blood eosinophils from atopic donors express messenger RNA for the alpha, beta, and gamma subunits of the high-affinity IgE receptor (Fc epsilon RI) and intracellular, but not cell surface, alpha subunit protein. J Allergy Clin Immunol. 2000;105:309–317
  35. Kayaba H, Dombrowicz D, Woerly G, Papin JP, Loiseau S, Capron M. Human eosinophils and human high affinity IgE receptor transgenic mouse eosinophils express low levels of high affinity IgE receptor, but release IL-10 upon receptor activation. J Immunol. 2001;167:995–1003
  36. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet. 1999;353:2213–2214
  37. van Rensen EL, Straathof KC, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax. 1999;54:403–408
  38. Turner MO, Johnston PR, Pizzichini E, Pizzichini MM, Hussack PA, Hargreave FE. Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial. Can Respir J. 1998;5:261–268
  39. Jayaram L, Pizzichini E, Lemiere C, Man SF, Cartier A, Hargreave FE, et al. Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast. Thorax. 2005;60:100–105
  40. Jayaram L, Duong M, Pizzichini MM, Pizzichini E, Kamada D, Efthimiadis A, et al. Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma. Eur Respir J. 2005;25:41–46

PII: S0954-6111(09)00310-2

doi: 10.1016/j.rmed.2009.09.011

Respiratory Medicine
Volume 104, Issue 2 , Pages 188-196 , February 2010

Article Tools

* Image Usage & Resolution